Diagnosing Antibiotic Resistance Using Nucleic Acid Enzymes and Gold Nanoparticles

ACS Nano. 2021 Jun 22;15(6):9379-9390. doi: 10.1021/acsnano.0c09902. Epub 2021 May 10.

Abstract

The rapid and accurate detection of antimicrobial resistance is critical to limiting the spread of infections and delivering effective treatments. Here, we developed a rapid, sensitive, and simple colorimetric nanodiagnostic platform to identify disease-causing pathogens and their associated antibiotic resistance genes within 2 h. The platform can detect bacteria from different biological samples (i.e., blood, wound swabs) with or without culturing. We validated the multicomponent nucleic acid enzyme-gold nanoparticle (MNAzyme-GNP) platform by screening patients with central line associated bloodstream infections and achieved a clinical sensitivity and specificity of 86% and 100%, respectively. We detected antibiotic resistance in methicillin-resistant Staphylococcus aureus (MRSA) in patient swabs with 90% clinical sensitivity and 95% clinical specificity. Finally, we identified mecA resistance genes in uncultured nasal, groin, axilla, and wound swabs from patients with 90% clinical sensitivity and 95% clinical specificity. The simplicity and versatility for detecting bacteria and antibiotic resistance markers make our platform attractive for the broad screening of microbial pathogens.

Keywords: DNAzyme; MRSA; RPA; antibiotic resistance; central line infection; gold nanoparticles; sepsis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Drug Resistance, Microbial
  • Gold
  • Humans
  • Metal Nanoparticles*
  • Methicillin-Resistant Staphylococcus aureus* / genetics
  • Microbial Sensitivity Tests
  • Nucleic Acids*
  • Staphylococcal Infections* / drug therapy

Substances

  • Anti-Bacterial Agents
  • Nucleic Acids
  • Gold